PharMerica Corp. (PMC) Stake Decreased by ClariVest Asset Management LLC
ClariVest Asset Management LLC lowered its stake in PharMerica Corp. (NYSE:PMC) by 1.6% during the second quarter, Holdings Channel reports. The fund owned 75,736 shares of the company’s stock after selling 1,237 shares during the period. ClariVest Asset Management LLC’s holdings in PharMerica Corp. were worth $1,867,000 at the end of the most recent reporting period.
A number of other institutional investors have also bought and sold shares of PMC. Louisiana State Employees Retirement System increased its position in PharMerica Corp. by 0.7% in the second quarter. Louisiana State Employees Retirement System now owns 13,600 shares of the company’s stock valued at $335,000 after buying an additional 100 shares during the last quarter. Boston Advisors LLC boosted its stake in PharMerica Corp. by 0.5% in the second quarter. Boston Advisors LLC now owns 19,985 shares of the company’s stock worth $493,000 after buying an additional 105 shares during the period. Capstone Asset Management Co. boosted its stake in PharMerica Corp. by 0.9% in the second quarter. Capstone Asset Management Co. now owns 12,321 shares of the company’s stock worth $304,000 after buying an additional 110 shares during the period. Springbok Capital Management LLC boosted its stake in PharMerica Corp. by 22.8% in the first quarter. Springbok Capital Management LLC now owns 7,000 shares of the company’s stock worth $155,000 after buying an additional 1,300 shares during the period. Finally, A.R.T. Advisors LLC boosted its stake in PharMerica Corp. by 6.5% in the first quarter. A.R.T. Advisors LLC now owns 29,467 shares of the company’s stock worth $651,000 after buying an additional 1,800 shares during the period. 92.37% of the stock is currently owned by hedge funds and other institutional investors.
PharMerica Corp. (NYSE:PMC) traded up 0.70% during midday trading on Wednesday, hitting $27.43. 188,625 shares of the company traded hands. PharMerica Corp. has a 12-month low of $19.79 and a 12-month high of $35.81. The company has a market capitalization of $843.86 million, a price-to-earnings ratio of 28.34 and a beta of 0.88. The stock’s 50-day moving average price is $26.66 and its 200 day moving average price is $25.24.
PharMerica Corp. (NYSE:PMC) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.47 EPS for the quarter, meeting the consensus estimate of $0.47. The business had revenue of $519.60 million for the quarter, compared to analysts’ expectations of $508.31 million. PharMerica Corp. had a net margin of 1.44% and a return on equity of 10.00%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.48 EPS. On average, equities analysts forecast that PharMerica Corp. will post $2.01 EPS for the current year.
Separately, Zacks Investment Research upgraded shares of PharMerica Corp. from a “sell” rating to a “hold” rating in a report on Friday, September 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the stock. PharMerica Corp. currently has a consensus rating of “Buy” and an average target price of $31.57.
About PharMerica Corp.
PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals, provides specialty infusion services to patients outside a hospital setting and offers the national oncology pharmacy in the United States.
Want to see what other hedge funds are holding PMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PharMerica Corp. (NYSE:PMC).
Receive News & Ratings for PharMerica Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PharMerica Corp. and related companies with MarketBeat.com's FREE daily email newsletter.